Theragnostics Opens U.S. Headquarters in Boston, Massachusetts
08/24/2017
Under the agreement, Theragnostics will distribute select ROTOP products in the U.S., Canada, Australia and New Zealand. In addition, ROTOP will manufacture GalliProst, Theragnostics' lead imaging candidate, and other agents in development, with distribution rights in the European Union and Switzerland.
Theragnostics' new headquarters is located in the historic Charlestown section of Boston, with close access to the region's prestigious teaching hospitals and global biotechnology hub. Products are expected to be available in the U.S. beginning September 1, 2017.
"Our relationship with ROTOP reflects our mission to serve the nuclear medicine community by delivering precisely targeted imaging and therapy agents for cancer patients and others," said Patrick Donahue, CEO, Theragnostics, Inc.
"It also supports our strategy to build revenue alongside the clinical development of our proprietary Galli® platform, which we believe will expand the power of PET imaging for thousands of physicians,” he added.
Project Announcements
Kimberly-Clark Expands Aiken County, South Carolina, Distribution Operations
05/04/2025
Aerowerks Plans Gaffney, South Carolina, Manufacturing Operations
05/04/2025
Sweden-Based Troax Group Plans Portland, Tennessee, Manufacturing Operations
05/04/2025
Kimberly-Clark Corporation Plans Warren, Ohio, Manufacturing Operations
05/04/2025
Denmark-Based Novonesis Expands Salem, Virginia, Production Operations
05/04/2025
Polyvlies USA Expands Winston-Salem, North Carolina, Manufacturing Operations
05/04/2025
Most Read
-
Run a Job Task Analysis
Q4 2024
-
39th Annual Corporate & 21st Annual Consultants Surveys: What Business Leaders and Consultants Are Saying About Site Selection
Q1 2025
-
The Location Economics of Advanced Nuclear
Q1 2025
-
Why Workforce Readiness Can’t Wait
Q1 2025
-
Power, Policy, and Site Selection in 2025
Q1 2025
-
Is It Time to Start Planning for Quantum Data Centers?
Q1 2025
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024